Influence fixed combination therapy on arterial stiffness and erectile function in patients with arterial hypertension
Article Sidebar
Main Article Content
Abstract
The aim – to evaluate the therapeutic efficacy and dynamics of arterial stiffness using сardio-ankle vascular index (CAVI), as well as the dynamics of erectile function in men of the generic fixed triple combination of valsartan/amlodipine/hydrochlorothiazide and a double fixed combination of valsartan/amlodipine in the treatment of patients with arterial hypertension II–III degree.
Materials and methods. The study included patients with moderate and severe arterial hypertension without diabetes. Patients were divided into 2 groups by the method of envelopes of 25 each. The first group (n=25) was assigned a fixed triple combination of tablets valsartan/amlodipine/hydrochlorothiazide. The drug was administered 1 tablet (160 mg of valsartan/5 mg of amlodipine/12.5 mg of hydrochlorothiazide) once a day in the morning for 1 month. Patients in the second group (n=25) received a similar scheme of a double fixed combination of the drug valsartan/amlodipine. The drug was administered 1 tablet (160 mg of valsartan/5 mg of amlodipine) once a day in the morning for 1 month. If necessary, the target level of office blood pressure was less than 140/90 mm Hg, the dose was titrated to a daily dose of 320/10/12.5 mg (valsartan/amlodipine/hydrochlorothiazide) on a fixed triple combination and up to 320/10 mg
(valsartan/amlodipine) on a fixed double combination. After 3 months of treatment there was control of therapy.
Results and discussion. The study included 50 patients with moderate and severe hypertension. The average age of patients was 54.9±1.8 (25–75) years. The average BMI is 31.2±0.7 kg/m2. The average of the office of SBP and DBP at the beginning of the study were 161.7±1.8 mm Hg and 98.5±1.4 mm Hg in accordance. The office heart rate is 70.7±1.4 bpm. The decrease in the office blood pressure (SBP/DBP) was 35/19 mm Hg (p<0.05) on the double combination and 42/26 mm Hg (p<0.05) on the triple combination. Achieving target BP measurement in the office was 90.9 % – in the double combination and 95.7 % – in triple combination. In the dual combination group, withdrawal was observed in
3 (6 %) patients, in the triple combination group, withdrawal was observed in 4 (8 %) patients. There was a tendency to decrease the stiffness of the arterial wall in terms of cardio-vascular index CAVI, but there was no significant difference. CAVI right on dual therapy up to 8.68±0.57 units and after treatment 8.30±0.55 units. CAVI on the left on double therapy to 8.49±1.49 units and after treatment 8.17±1.49 units. CAVI right on triple therapy up to 8.86±0.39 units and after treatment 8.50±0.40 units from CAVI on the left in a triple combination up to 8.09±0.53 units and after treatment 8.27±0.36 units (p>0.05 for all values). No significant change in erectile function in men was detected during treatment.
Conclusion. The dual (valsartan/amlodipine) and triple (valsartan/amlodipine/hydrochlorothiazide) fixed combination showed high antihypertensive efficacy, did not adversely affect metabolic disorders and erectile function in men, and inhibited the progression of stiffness.
Article Details
Keywords:
References
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // JAMA.– 2002.– Vol. 18; 288 (23).– P. 2981–2997. doi: 10.1001/jama.288.23.2998.
Aranda P., Ruilope L.M., Calvo C. et al. Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study // Am. J. Hypertens.– Vol. 17 (2).– P. 139–145. doi: 10.1016/j.amjhyper.2003.09.006.
Bukuda K., Ichihara A., Sakoda M. et al. Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome // Vasc. Health Risk. Manag.– 2010.– Vol. 6.– P. 571–578. doi: 10.2147/vhrm.s11958.
Calhoun D.A., Lacourciere Y., Crikelair N. et al. Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension // Curr. Med. Res. Opin.– 2013.– Vol. 29.– P. 901–910. doi: 10.1185/03007995.2013.803057.
Choi S.Y., Oh B.H., Park J.B. et al. Age-associated increase in arterial stiffness measured according to the cardio-ankle vascular index without blood pressure changes in healthy adults // J. Atheroscler. Thromb.– 2013.– Vol. 20.– P. 911–923. doi: 10.5551/jat.18267.
Doumas M., Tsakiris A., Douma S. et al. Factors affecting the increased prevalence of erectile dysfunction in Greek hypertensive compared with normotensive subjects // J. Androl. – 2006.– Vol. 27 (3).– P. 469–477. doi: 10.2164/jandrol.04191.
Greenstein A., Chen J., Miller H. et al. Does severity of ischemic coronary disease correlate with erectile function? // Int. J. Impot. Res. – 1997.– Vol. 9 (3).– P. 123–126. doi: 10.1038/sj.ijir.3900282.
Horinaka S., Yabe A., Yagi H. et al. Comparison of atherosclerotic indicators between cardio ankle vascular index and brachial ankle pulse wave velocity // Angiology.– 2009.– Vol. 60 (4).– P. 468–476. doi: 10.1177/0003319708325443.
Ibata J., Sasaki H., Kakimoto T. et al. Cardio-ankle vascular index measures arterial wall stiffness independent of blood pressure // Diabetes. Res. Clin. Pract.– 2008.– Vol. 80 (2).– P. 265–270. doi: 10.1016/j.diabres.2007.12.016.
Mehlum M., Liestøl K., Julius S. et al. visit-to-visit blood pressure variability increases risk of stroke or cardiac events in patients given valsartan or amlodipine in the VALUE trial // J. Hypertens.– 2015.– Vol. 33 (Suppl. 1).– P. e40. doi: 10.1097/01.hjh.0000467454.55397.ea.
Miyashita Y., Endo K., Saiki A. et al. Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients // J. Atheroscler. Thromb.– 2009.– Vol. 16.– P. 539–545. doi: 10.5551/jat.281.
Miyashita Y., Saiki A., Endo K. et al. Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension // J. Atheroscler. Thromb.– 2009.– Vol. 16.– P. 621–626. doi: 10.5551/jat.497.
Nakayama K., Kuwabara Y., Daimon M. et al. Valsartan Amlodipine Randomized Trial (VART): design, methods, and preliminary results // Hypertens. Res.– 2008.– Vol. 31 (1).– P. 21–28. doi: 10.1291/hypres.31.21.
Namekata T., Suzuki K., Ishizuka N., Shirai K. Establishing baseline criteria of cardio-ankle vascular index as a new indicator of arteriosclerosis: a cross-sectional study // BMC Cardiovasc. Disord.– 2011.– Vol. 11.– P. 51. doi: 10.1186/1471-2261-11-51.
Saiki A., Sato Y., Watanabe R. et al. The Role of a Novel Arterial Stiffness Parameter, Cardio-Ankle Vascular Index (CAVI), as a Surrogate Marker for Cardiovascular Diseases // J. Atheroscler. Thromb.– 2016.– Vol. 23 (2).– P. 155–168. doi: 10.5551/jat.32797.
Satoh N., Shimatsu A., Kato Y. et al. Evaluation of the cardio-ankle vascular index, a new indicator of arterial stiffness independent of blood pressure, in obesity and metabolic syndrome // Hypertens. Res.– 2008.– Vol. 31 (10).– P. 1921–1930. doi: 10.1291/hypres.31.1921.
Sawada T., Yamada H., Dahlf B., Matsubara H., for the KYOTO HEART Study Group. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study // Eur. Heart J.– 2009.– Vol. 30.– P. 2461–2469. doi: 10.1093/eurheartj/ehp363.
Shirai K., Utino J., Otsuka K., Takata M. A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI) // J. Atheroscler. Thromb.– 2006.– Vol. 13 (2).– P. 101–107. doi: 10.5551/jat.13.101.
Shirai K., Song M., Suzuki J. et al. Contradictory effects of β1- and α1-aderenergic receptor blockers on cardio-ankle vascular stiffness index (CAVI) – CAVI independent of blood pressure // J. Atheroscler. Thromb.– 2011.– Vol. 18 (1).– P. 49–55. doi: 10.5551/jat.3582.
Sison J., Ríos Vega R.M., Dayi H. et al. Efficacy and effectiveness of valsartan/amlodipine and valsartan/amlodipine/hydrochlorothiazidein hypertension: randomized-controlled versus observational studies // Cur. Med. Research and Opinion. doi: 10.1080/03007995.2017.1412682.
Takaki A., Ogawa H., Wakeyama T. et al. Cardio-ankle vascular index is superior to brachial-ankle pulse wave velocity as an index of arterial stiffness // Hypertens. Res.– 2008.– Vol. 31 (7).– P. 1347–1355. doi: 10.1291/hypres.31.1347.
Uehara G., Takeda H. Relative effects of telmisartan, candesartan and losartan on alleviateing arterial stiffnes inpatients with hypertension complicated by diabetes mellitus: An evaluation using the cardiovascular index // J. Inter. Medical. Res.– 2008.– Vol. 36.– P. 1094–1102. doi: 10.1177/147323000803600529.
Wang L., Zhao J.W., Liu B. et al. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis // Am. J. Cardiovasc. Drugs.– 2012.– Vol. 12 (5).– P. 335–344. doi: 10.2165/11597390-000000000-00000.
Williams B., Mancia G., Spiering W. et al. Authors/Task Force Members:. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension // J. Hypertens.– 2018.– Vol. 36.– P. 1953–2041. doi: 10.1097/HJH.0000000000001940.
Yamamoto N., Yamanaka G., Ishikawa M. et al. Cardio-ankle vascular index as a predictor of cognitive impairment in community-dwelling elderly people: four-year follow-up // Dement. Geriatr. Cogn. Disord.– 2009.– Vol. 28 (2).– P. 153–158. doi: 10.1159/000235642.